Immunotherapy combination helps patients with resistant melanoma
Separate immunotherapies work well together, pumping up the impact of immune system attack on tumors, an unprecedented clinical trial shows this week in the Journal of Clinical Oncology.
Capturing tumor-homing T cells from a patient’s blood, expanding and priming them in the lab, and then giving the cells back, along with a drug that keeps them from getting turned off, improved the prospects of patients with metastatic melanoma...
Advances in gynecologic cancer treatments presented at ASCO
Advances that could change gynecologic cancer standard–of-care treatments are the centerpiece of key studies were presented by researchers...
Cost of chemo for breast cancer varies widely
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new...
Should treatment choices be based on gender?
It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
A study at MD Anderson Cancer Center reviewed 13 cancer types and provided a molecular understanding of sex effects in diverse cancers. The research revealed two cancer-type groups associated with cancer incidence and mortality, suggesting a “pressing...
The dream team vs. rare heart tumors
When Gene Duncan visited his family doctor for a respiratory infection, little did he realize he’d be diagnosed with bronchitis — and something...
Sights set on first targeted therapy for triple-negative breast cancer
An MD Anderson study is seeking new drugs to combat triple-negative breast cancer, an aggressive form of the disease that doesn’t rely on...
Immunotherapy drug helps advanced bladder cancer patients
The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless...
Extending lung cancer patients’ survival
Lung cancer patients whose cancer has spread to three or fewer sites may benefit from aggressive surgery or radiation after completing standard...